Results 91 to 100 of about 12,992 (201)

High Proportion of PNH Type II Neutrophils Is Associated With Thrombosis in Patients Displaying a PNH Clone ≥ 1%

open access: yesAmerican Journal of Hematology, Volume 101, Issue 9, Page 2311-2328, September 2026.
ABSTRACT The clinical significance of PNH Type II white blood cells (WBCs) remains unclear. We assessed the relative percentage (rel%) of Type II neutrophils in 355 patients with a PNH clone ≥ 1% on neutrophils enrolled by 33 flow cytometry laboratories in the 5‐year French nation‐wide multicenter prospective observational study.
Orianne Wagner‐Ballon   +41 more
wiley   +1 more source

Clinical and cost-effectiveness of eculizumab withdrawal in atypical haemolytic uraemic syndrome: the SETS aHUS multi-centre, open-label, prospective and single-arm study

open access: yesHealth Technology Assessment
Background Atypical haemolytic uraemic syndrome is a rare disease (incidence: 0.4 cases per million per year) which, without treatment, is associated with high morbidity and mortality.
Andrew Bryant   +18 more
doaj   +1 more source

Successful pregnancy outcome in paroxysmal nocturnal hemoglobinuria (PNH) following escalated eculizumab dosing to control breakthrough hemolysis

open access: yesLeukemia Research Reports, 2015
Pregnancy in women with paroxysmal nocturnal hemoglobinuria (PNH) is associated with increased maternal and fetal morbidity and mortality. There is limited published experience regarding therapy of PNH during pregnancy.
Ruby Sharma   +4 more
doaj   +1 more source

Cytokine‐Driven Hyperinflammation in Long COVID: Mechanisms, Biomarkers, Complement Dysregulation, and Emerging Immunotherapies—A Narrative Review

open access: yesHealth Science Reports, Volume 9, Issue 9, September 2026.
ABSTRACT Background and Aims Long COVID, also known as post‐acute sequelae of SARS‐CoV‐2 infection (PASC), is a multisystem condition characterized by persistent symptoms that continue beyond the acute phase of infection. Growing evidence indicates that sustained immune dysregulation involving cytokine‐mediated inflammation, complement activation ...
Emmanuel Ifeanyi Obeagu
wiley   +1 more source

Eculizumab in the management of paroxysmal nocturnal hemoglobinuria: patient selection and special considerations

open access: yes, 2016
Fatimah Al-Ani,1 Ian Chin-Yee,1 Alejandro Lazo-Langner1,2 1Department of Medicine, Division of Hematology, 2Department of Epidemiology and Biostatistics, Western University, London, ON, Canada Abstract: Paroxysmal nocturnal hemoglobinuria (PNH) is a ...
Chin-Yee I, Lazo-Langner A, Al-Ani F
core  

Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT

open access: yesFrontiers in Immunology, 2019
The treatment of paroxysmal nocturnal hemoglobinuria has been revolutionized by the introduction of the anti-C5 agent eculizumab; however, eculizumab is not the cure for Paroxysmal nocturnal hemoglobinuria (PNH), and room for improvement remains. Indeed,
Antonio M. Risitano   +15 more
doaj   +1 more source

Eculizumab in pregnancy: a narrative overview

open access: yes, 2019
Pregnancy can be a dangerous trigger for patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), or hemolysis, elevated liver enzymes and low platelet (HELLP) syndrome. Due to the possibility of several serious
Tufano A.   +5 more
core   +1 more source

Adjustment of Eculizumab Dosage Pattern in Patients with Atypical Hemolytic Uremic Syndrome with Suboptimal Response to Standard Treatment Pattern

open access: yesCase Reports in Nephrology, 2016
In patients with atypical hemolytic uremic syndrome (aHUS), complement blocking by eculizumab rapidly halts the process of thrombotic microangiopathy and it is associated with clear long-term hematologic and renal improvements.
Camino García Monteavaro   +7 more
doaj   +1 more source

Eccrine Squamous Syringometaplasia Mimicking Acute Cutaneous GVHD in a Pediatric HSCT Recipient: Case Report and Brief Review of the Indexed Literature

open access: yesJournal of Cutaneous Pathology, Volume 53, Issue 9, Page 792-802, September 2026.
ABSTRACT Eccrine squamous syringometaplasia (ESS) is an uncommon reactive alteration of eccrine ducts, most often reported in oncologic and transplant settings, where it may clinically mimic acute cutaneous graft‐versus‐host disease (GVHD). We describe a 3‐year‐old boy with chronic granulomatous disease who developed a diffuse erythematous eruption 6 ...
Benedetta Galli   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy